DexCom, Inc. (Nasdaq: DXCM) reported its financial results for the third quarter ended September 30, 2026, in a filing with the U.S. Securities and Exchange Commission. The company announced that its revenue grew 11% year-over-year to $1.344 billion on a reported basis, with organic revenue growth also reaching 11%.
On a geographic basis, U.S. revenue increased 14% year-over-year, while international revenue grew 5%. The company reported GAAP operating income of $327.2 million, or 24.3% of revenue, an increase of 420 basis points compared to the prior year period. Non-GAAP operating income was $339.5 million, or 25.3% of reported revenue, representing an increase of 270 basis points.
DexCom also updated its fiscal year 2026 guidance. The company raised the midpoint of its revenue guidance to $5.20 - $5.25 billion, which represents approximately 12-13% growth. Additionally, the company increased its guidance for Non-GAAP Operating Margin to approximately 24% and Adjusted EBITDA Margin to approximately 32%.
In other business developments, DexCom announced that its Board of Directors has authorized a share repurchase program of up to $1.0 billion of the company’s outstanding common stock. The repurchase period is set to end no later than December 31, 2027. Repurchases may be made in the open market or through privately negotiated transactions, subject to market conditions and applicable laws.
As of September 30, 2026, DexCom held $1.82 billion in cash, cash equivalents, and marketable securities, with its revolving credit facility remaining undrawn.
